Tests personalized magnetic brain stimulation in adults with schizophrenia
Tests personalized magnetic brain stimulation for schizophrenia symptoms in adults.
Plain-language title generated from the registry record
Registry title: Personalized iTBS in Real-World Clinical Settings for Schizophrenia
Key facts
- Where
- Hefei, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07176468, who can take part
Where in China
- Anhui Medical UniversityHefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anhui Medical University
- Trial code
- NCT07176468
- Record updated
- 30 December 2025
- Original description
This study is designed to determine whether neuronavigation-guided, personalized Intermittent Theta-Burst Stimulation (iTBS) can produce clinically benefits for patients with schizophrenia when delivered in real-world treatment settings. By situating the intervention within real-world treatment settings-without imposing restrictions on concurrent pharmacotherapy-this trial seeks to generate evidence that is both scientifically rigorous and clinically relevant.Read full original descriptionShow less
Efficacy of Personalized iTBS in Real-World Clinical Settings for Alleviating Schizophrenia Symptoms : A Randomized Single-Blind Trial
This study is designed to determine whether neuronavigation-guided, personalized Intermittent Theta-Burst Stimulation (iTBS) can produce clinically benefits for patients with schizophrenia when delivered in real-world treatment settings. By situating the intervention within real-world treatment settings-without imposing restrictions on concurrent pharmacotherapy-this trial seeks to generate evidence that is both scientifically rigorous and clinically relevant.
The main questions it seeks to address are:
Does the personalized iTBS target TMS protocol improve clinical symptoms in patients with schizophrenia within real-world treatment settings? What neural circuit changes, as assessed by functional MRI, occur following TMS treatment?
Participants will:
Undergo personalized,personalized iTBS target treatment daily for 2 weeks. Complete baseline and post-treatment assessments, including clinical symptom scales (PANSS, HAMA, HAMD) and neuropsychological tests (MoCA, DST, VFT, Stroop Test, and AVLT).
Have structural and resting-state functional MRI scans before and after treatment.
Be monitored for any treatment-related adverse events.
Inclusion: Aged 18-60 years, any gender; Meets DSM-5 criteria for schizophrenia; Antipsychotic medication change (initiation, dose adjustment, or switch) occurred within the past 3 days; Capable of understanding the study and providing written informed consent Able to comply with study procedures and complete assessments.
Exclusion: Contraindications to MRI or TMS (e.g., metal implants, pacemakers); Major neurological disorders (e.g., epilepsy, organic brain lesions, severe head trauma); Active suicidal ideation or behavior; Pregnancy or lactation; Receipt of TMS or ECT within the past 6 months; Judged by investigators to be unsuitable for participation.